Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Alnylam Pharmaceuticals Inc (ALNY.O)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (US$)	Price Target (US$)	Rating
2022-04-08	163.42	211.00	Buy
2022-05-19	129.36	204.00	Buy
2022-08-11	229.39	-	No Rating
2022-08-17	223.13	266.00	Buy
2023-08-04	185.58	256.00	Buy
2023-10-23	162.00	253.00	Buy
2024-06-28	243.00	288.00	Buy
2024-08-16	268.24	308.00	Buy
2024-11-01	273.91	310.00	Buy
2025-02-14	256.45	331.00	Buy
2025-05-02	259.39	349.00	Buy
2025-06-18	312.32	398.00	Buy

Disclosures

UBS Securities LLC makes a market in the securities and/or ADRs of this company.
UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.